Skip to main content
SpringerLink
Log in

A protein puzzle: Untangling the mysterious condition of amyloidosis

  • News
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A Correction to this article was published on 07 April 2017

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 23 March 2017

    In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis’ NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIOTTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.

Author information

Authors and Affiliations

  1. Shraddha Chakradhar is Nature Medicine's associate news editor in Boston.,

    Shraddha Chakradhar

Authors
  1. Shraddha Chakradhar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chakradhar, S. A protein puzzle: Untangling the mysterious condition of amyloidosis. Nat Med 23, 266–269 (2017). https://doi.org/10.1038/nm0317-266

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0317-266

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation